Author(s):
Wenny Putri Nilamsari, Mochamad Yusuf Alsagaff, Aminatush Sholichah, Ela Agustin, Meuthia Handayani, Halim Priyahau jaya, Budi Suprapti, Arina Dery Puspita Sari
Email(s):
wenny-p-n@ff.unair.ac.id
DOI:
10.52711/0974-360X.2025.00774 
Address:
Wenny Putri Nilamsari1*, Mochamad Yusuf Alsagaff2, Aminatush Sholichah3, Ela Agustin3, Meuthia Handayani3, Halim Priyahau jaya4, Budi Suprapti1, Arina Dery Puspita Sari1
1Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
2Department of Cardiology and Vascular, Dr Soetomo Teaching Hospital, Surabaya, Indonesia.
3Master of Clinical Pharmacy Program, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
4Department of Pharmacy, Dr Soetomo Teaching Hospital, Surabaya, Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 11,
Year - 2025
ABSTRACT:
The 2019 ESC guidelines recommend more aggressive LDL-C reduction relative to the 2016 guideline. Despite the high prevalence of CVD in Indonesia, there are no publications on the attainment of LDL-C level consistent with the ESC 2019 guidelines. This research aims to examine LDL-C objectives and the the key determinants affecting their attainment. The study procedures were carried out using a prospective cross-sectional method in a tertiary hospital. The sample population consisted 304 patients, with the majority being males (69.41%) aged 56-70 years (57.24%). The results indicated that merely 5.59% of patients attained LDL-C target, including 15 with very high risk (4.93%) and 2 with high risk (0.66). In addition, the influential factors in this study were male (OR 5.680), not smoking (OR 3.080), and adherence (OR 3.441). These results showed that achievement was very low based on the 2019 ESC guidelines. Therefore, further intervention from health professionals was needed to enhance the number of patients attaining the LDL-C objective.
Cite this article:
Wenny Putri Nilamsari, Mochamad Yusuf Alsagaff, Aminatush Sholichah, Ela Agustin, Meuthia Handayani, Halim Priyahau jaya, Budi Suprapti, Arina Dery Puspita Sari. Very Low Achievement of LDL-C Targets Based On 2019 ESC Guidelines and Factors Associated with Low Achievement of LDL-C Target. Research Journal Pharmacy and Technology. 2025;18(11):5370-6. doi: 10.52711/0974-360X.2025.00774
Cite(Electronic):
Wenny Putri Nilamsari, Mochamad Yusuf Alsagaff, Aminatush Sholichah, Ela Agustin, Meuthia Handayani, Halim Priyahau jaya, Budi Suprapti, Arina Dery Puspita Sari. Very Low Achievement of LDL-C Targets Based On 2019 ESC Guidelines and Factors Associated with Low Achievement of LDL-C Target. Research Journal Pharmacy and Technology. 2025;18(11):5370-6. doi: 10.52711/0974-360X.2025.00774 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-11-36
REFERENCES:
1. Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016; 118(4): 535-546. doi:https://doi.org/0.1161/CIRCRESAHA.115.307611
2. Nelson S, Whitsel L, Khavjou O, Phelps D, Leib A. Projections of Cardiovascular Disease Prevalence and Costs: 2015-2035. RTI International; 2016.
3. World Health Organization. Coronary Heart Disease Deaths in Indonesia. Published online 2020.
4. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. The Lancet. 2020; 395(10226): 795-808. doi:10.1016/S0140-6736(19)32008-2.
5. Kaur S, Devendra, Rai S. Coronary Artery Disease: An Overview. A and V Pub Journal of Nursing and Medical Research. 2023; 1; 2(1): 22-24. doi:10.52711/jnmr.2023.07.
6. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Primer Aug. 2019; 16; 5(1): 56. doi:10.1038/s41572-019-0106-z.
7. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Consens Statement Eur Atheroscler Soc Consens Panel Eur Heart J. 2017; 38(32): 2459-2472. doi:10.1093/eurheartj/ehx144
8. Mankar SD, Pawar BV, Pawar TY. Lipoprotein, Cholesterol, Treatment Strategies, and its Impact on Cardiovascular Diseases. Research Journal of Pharmacology and Pharmacodynamics. 2024; 16(3): 185-191. doi: 10.52711/2321-5836.2024.00032.
9. Jadhav KL, Kapare PR, Khairmode DV, Keskar CH, Shaikh F, Sawant S, Mali AS. Genetic Insight of Cholesterol and Atherosclerosis: Complex Biology. Asian Journal of Pharmaceutical Research. 2018; 8(3): 175-184. doi: 10.5958/2231-5691.2018.00031.X.
10. Abdullah SM, Defina LF, Leonard D, et al. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. 2018; 138(21): 2315-2325. doi:10.1161/CIRCULATIONAHA.118.034273
11. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC. Eur Atheroscler Soc EAS Eur Heart J. 2020; 41(ue1): 111-188,. doi:10.1093/eurheartj/ehz455
12. Kalaivanan S, Sarumathy S, Ebens JA, Kumar NK, Parveen AR, Ashraf M. Clinical Assessment and Comparison of Lipid Profiles among Coronary Artery Disease and type 2 Diabetes Mellitus Patients receiving Statin Therapy. Research J. Pharm and Tech. 2017; 10(1):18-20. doi: 10.5958/0974-360X.2017.00005.1.
13. Danchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS. Eur J Prev Cardiol. 2018; 25(10): 1087-1094. doi:10.1177/2047487318777079.
14. Presta V, Figliuzzi I, Miceli F, et al. Achievement of low-density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: analysis of a large real practice database in Italy. Atherosclerosis. 2019; 285: 40-48. doi:10.1016/j.atherosclerosis.2019.03.017.
15. Bruckert E, Parhofer KG, Gonzalez-Juanatey N JR, et al. Proportion of high-risk/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review. Adv Ther. 2020; 37: 1724-1736. doi:10.1007/s12325-020-01285-2
16. Indonesia Minister of Health. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/6485/2021 Tentang Formularium Nasional. Published online 2021.
17. Barati M, Taheri-Kharameh Z, Bandahelahi K, Yeh VM, and Kripalani S. Validation of the short form of the aherence to refills and medication scale in iranian elders with chronic disease. Journal of Clinical and Diganostic Research. 2018: 12(11): 10-13. doi: http://doi.org/10/7860/JCDR/2018/37584.12305
18. Senthilkumar, Tamilselvi. Risk Farctos of Cardiovascular Diseases in Adolescents: A systematic review. Asian Journal of Nursing Education and Research. 2021; 11(1): 151-156. doi: 10.5958/2349-2996.2021.00039.2.
19. Gao Z, Chen Z, Sun A, Deng X. Gender differences in cardiovascular disease. Med Nov Technol Devices. 2019; 4: 100025. doi:10.1016/j.medntd.2019.100025
20. Yudin ZM, Yaacob LH, Hassan NB, Ismail SB, Draman N, Yusoff SSM. Achievement of LDL cholesterol goal and adherence to statin by diabetes patients in Kelantan. Malays J Med Sci MJMS. 2017; 24(3): 44. doi:10.21315/mjms2016.24.3.6.
21. Aryan L, Younessi D, Zargari M, et al. The role of estrogen receptors in cardiovascular disease. Int J Mol Sci. 2020; 21(12): 4314. doi:10.3390/ijms21124314
22. Suthar VB, Shah JS, Bhatt PA, Patel SB. Significance of Esterogen in Acute Coronary Syndrome. Research J. Pharmacology and Pharmacodinamics. 2011; 3(4); 210-214.
23. Degano IR, Marrugat J, Grau M, et al. The association between education and cardiovascular disease incidence is mediated by hypertension, diabetes, and body mass index. Sci Rep. 2017; 7(1): 12370. doi:10.1038/s41598-017-10775-3
24. Petrelli A, Sebastiani G, Napoli A, et al. Education inequalities in cardiovascular and coronary heart disease in Italy and the role of behavioral and biological risk factors. Nutr Metab Cardiovasc Dis. 2021; 32: 918-928. doi:10.1016/j.numecd.2021.10.022.
25. Varghese N, Shine J. A Study to assess the knowledge regarding prevention of Cardiovascular Diseases (CVD) among Obese women in selected urban community areas at Mangalore. Asian Journal of Nursing Education and Research. 2021; 11(3); 387-390. doi: 10.52711/2349-2996.2021.00093.
26. Dubey SR. A Descriptive Study to Assess the Knowledge of Adolescents regarding Obesity as a Predisposing Factor for Cardiovascular Diseases with A View to Develop an Educational Pamphlet in selected Urban Areas to Tumkur. International Journal of Avances in Nursing Management. 2021; 9(3); 319-321. doi: 10.52711/2454-2652.2021.00072.
27. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic status and cardiovascular outcomes: challenges and interventions. Circulation. 2018; 137(20): 2166-2178. doi:10.1161/CIRCULATIONAHA.117.029652.
28. Pereira JL, Castro MA, Leite JM, et al. Overview of cardiovascular disease risk factors in adults in São Paulo, Brazil: prevalence and associated factors in 2008 and 2015. Int J Cardiovasc Sci. 2022;35:230-242. doi:10.36660/ijcs.20210076
29. Ratna JVV, Vemoadapu M, Kolakota Rk, Mugada V. Risk of Cardiovascular Disease in Schizophrenia: A Mini Review. Asian Journal of Research in Pharmaceutival Sciences. 2019; 9(2); 131-136. doi: 10.5958/2231-5659.2019.00019.5.
30. Oyama K, Giugliano RP, Blazing MA, et al. Baseline low-density lipoprotein cholesterol and clinical outcomes of combining ezetimibe with statin therapy in IMPROVE-IT. J Am Coll Cardiol. 2021; 78(15): 1499-1507. doi:10.1016/j.jacc.2021.08.011
31. Johannesen CDL, Langsted A, Mortensen MB, Nordestgaard BG. Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study. BMJ. 2021; n422. doi:10.1136/bmj.m4266.
32. Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022; 134(8): 752-762. doi:10.1080/00325481.2022.211749.
33. Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev. 2021; 26: 1359-1370. doi:10.1007/s10741-020-09979-z
34. Guglielmi V, Bellia A, Pecchioli S, et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis. 2017; 263: 36-41. doi:10.1016/j.atherosclerosis.2017.05.018
35. Alwhaibi M, Altoaimi M, AlRuthia Y, et al. Adherence to statin therapy and attainment of LDL cholesterol goal among patients with type 2 diabetes and dyslipidemia. Patient Prefer Adherence. Published online 2019: 2111-2118. doi:10.2147/PPA.S231873
36. Beernink JM, Oosterwijk MM, Boven JFM, et al. Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT. Front Pharmacol. 2022;13(888110). doi:10.3389/fphar.2022.888110.
37. Alfian SD, Annisa N, Fajriansyah F, et al. Modifiable Factors Associated with Non-adherence to Antihypertensive or Antihyperlipidemic Drugs Are Dissimilar: a Multicenter Study Among Patients with Diabetes in Indonesia. J Gen Intern Med. Published online 2020. doi:10.1007/s11606-020-05809-y.
38. Morotti K, Lopez J, Vaupel V, Swislocki A, Siegel D. Adherence to and persistence with statin therapy in a veteran population. Ann Pharmacother. 2019;53(1):43-49. doi:10.1177/1060028018792702
39. Ofori-Asenso R, Ilomäki J, Tacey M, et al. Predictors of first‐year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. Br J Clin Pharmacol. 2019; 85(1): 227-235. doi:10.1111/bcp.13797.
40. Katzmann JL, Mahfoud F, Böhm M, Schulz M, Laufs U. Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. Patient Prefer Adherence. Published online 2018: 9-19. doi:10.2147/PPA.S182765.
41. Başaran Ö, Doğan V, Mert KU, et al. How did the updated 2019 European Society of Cardiology/European Atherosclerosis Society risk categorization for patients with diabetes affect the risk perception and lipid goals? A simulated analysis of real-life data from EPHESUS study. Anatol J Cardiol. 2023; 27(2): 78-87. doi:10.14744/AnatolJCardiol.2022.2012
42. Meier R, Rachamin Y, Rosemann T, Markun S. The impact of the 2019 European guideline for cardiovascular risk management: a cross-sectional study in general practice. J Clin Med. 2020;9(7):2140. doi:10.3390/jcm9072140.
43. Haegale M. Achievement of Low-Density Lipoportein Cholesterol Tergets in Cardiac Rehabilitation: Impact of the 2019 ESC/EAS Dyslipidemia Guidelines. J Clin Med. Published online 2022:1-9.
44. Gavina C, Araújo F, Teixeira C, et al. Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study. Atherosclerosis. Published online 2023. doi:10.1016/j.atherosclerosis.2023.05.017
45. Rachamin Y, Grischott T, Rosemann T, Meyer MR. Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: A large-scale, cross-sectional study in primary care. Atherosclerosis. 2021; 324: 141-147. doi:10.1016/j.atherosclerosis.2019.03.017.
46. Kotseva K, Wood D, Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23(6): 636-648. doi:10.1177/2047487315569401.
47. Brown CJ, Chang LS, Hosomura N, et al. Assessment of sex disparities in nonacceptance of statin therapy and low-density lipoprotein cholesterol levels among patients at high cardiovascular risk. JAMA Netw Open. 2023; 6(2): 231047-23104. doi:10.1001/jamanetworkopen.2023.1047
48. Nanna MG, Wang TY, Xiang Q, et al. Sex differences in the use of statins in community practice: patient and provider assessment of lipid management registry. Circ Cardiovasc Qual Outcomes. 2019; 12(8): 005562. doi:10.1161/CIRCOUTCOMES.118.005562
49. Sara C, Ouidad A, Islam B, Yousra GI, Samir D. The effect of Chronic Tobacco smoking on Atherogenic index and Cardiovascular diseases risk in El-Oued (Algeria) Men. Asian J.Research Chem. 2020; 13(6); 489-493. doi: 10.5958/0974-4150.2020.00086.3.
50. Talic S, Marquina C, Zomer E, et al. Attainment of low-density lipoprotein cholesterol goals in statin treated patients: Real-world evidence from Australia. Curr Probl Cardiol. 2022;47(7):101068. doi:10.1016/j.cpcardiol.2021.101068.
51. Tan NC, Koh EYL, Goh CC, Goh PSC, Koh KH. A cross-sectional study of gender differences in lifestyle behavior and usage of medications among community-dwelling Asians towards achieving their LDL-Cholesterol treatment goals. Proc Singap Healthc. 2017; 26(3): 158-165. doi:10.1177/2010105817694906
52. Nakamura M, Yamamoto Y, Imaoka W, et al. Relationships between Smoking Status, Cardiovascular Risk Factors, and Lipoproteins in a Large Japanese Population. J Atheroscler Thromb. 2021; 1; 28(9):942-953. doi:10.5551/jat.5683s8
53. Piepoli MF, Hoes AW, Agewall S, et al. Guidelines: Editor’s choice: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Dev Spec Contrib Eur Assoc Cardiovasc Prev Rehabil EACPR Eur Heart J. 2016; 37(29): 2315. doi:10.1093/eurheartj/ehw106
54. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121(6):750-758. doi:10.1161/CIRCULATIONAHA.109.891523
55. Brown R, Lewsey J, Wild S, Logue J, Welsh P. Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort study. BMJ Open. 2021;11(9):054893. doi:10.1136/bmjopen-2021-054893
56. Bansilal S, Castellano JM, Garrido E, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J Am Coll Cardiol. 2016; 68(8): 789-801. doi:10.1016/j.jacc.2016.06.005
57. Trier T, Mohammadnia N, Snaterse M, Peters R, Jørstad H, Bax W. Lifestyle management to prevent atherosclerotic cardiovascular disease: evidence and challenges. Neth Heart J. 2022; 30(1): 3-14. doi:10.1007/s12471-021-01642-y
58. Oñatibia-Astibia A, Malet-Larrea A, Larrañaga B, Gastelurrutia, MÁ, Calvo B, Ramírez D, Cantero I, Garay Á, and Goyenechea E. Tailored interventions by community pharmacists and general practitioners improve adherence to statins in a Spanish randomized controlled trial. Health Services Research. 2019. 54(3): 658-668. doi: https://doi.org/10.1111/1475-6773.13152